These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16248836)

  • 1. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
    Fontana E; Dansette PM; Poli SM
    Curr Drug Metab; 2005 Oct; 6(5):413-54. PubMed ID: 16248836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
    Kalgutkar AS; Obach RS; Maurer TS
    Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).
    Kamel A; Harriman S
    Drug Discov Today Technol; 2013; 10(1):e177-89. PubMed ID: 24050247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
    VandenBrink BM; Isoherranen N
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
    Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
    Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective.
    Kumar S; Sharma R; Roychowdhury A
    Curr Med Chem; 2012; 19(21):3605-21. PubMed ID: 22680629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
    Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
    Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
    Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
    Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
    Zhou SF; Xue CC; Yu XQ; Li C; Wang G
    Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.
    Ha-Duong NT; Dijols S; Macherey AC; Goldstein JA; Dansette PM; Mansuy D
    Biochemistry; 2001 Oct; 40(40):12112-22. PubMed ID: 11580286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme kinetics for clinically relevant CYP inhibition.
    Zhang ZY; Wong YN
    Curr Drug Metab; 2005 Jun; 6(3):241-57. PubMed ID: 15975042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A; Komorowski J; Wikberg JE
    J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
    He K; Woolf TF; Hollenberg PF
    J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K; Khattar SK; Saini KS
    Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiton of cytochrome P450 isoenzymes and P-gp activity by multiple extracts of Huang-Lian-Jie-Du decoction.
    Wang Y; Jiang YM; Wang YT; Kang JW; Yu T; Zhao HY; Bian BL; Huang M; Bi HC
    J Ethnopharmacol; 2014 Oct; 156():175-81. PubMed ID: 25219605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational models for predicting interactions with cytochrome p450 enzyme.
    Arimoto R
    Curr Top Med Chem; 2006; 6(15):1609-18. PubMed ID: 16918472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation.
    Zhang T; Rao J; Li W; Wang K; Qiu F
    Drug Metab Rev; 2020 Nov; 52(4):501-530. PubMed ID: 33043714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
    Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T
    Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of cannabidiol-mediated cytochrome P450 inactivation.
    Bornheim LM; Everhart ET; Li J; Correia MA
    Biochem Pharmacol; 1993 Mar; 45(6):1323-31. PubMed ID: 8466552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.